Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer

Cancer Genomics and Proteomics

Volumn 8, Issue 2, 2011, Pages 87-92

  Nishioka, Masanori ^a   Shimada, Mitsuo ^a   Kurita, Nobuhiro ^a   Iwata, Takashi ^a   Morimoto, Shinya ^a   Yoshikawa, Kozo ^a   Higashijima, J U N ^a   Miyatani, Tomohiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Chemoradiotherapy; Focused DNA microarray; Gene expression profiling; Rectal cancer; S 1; Tailored therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BETA INTEGRIN; DNA TOPOISOMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRILYSIN; MATRIX METALLOPROTEINASE; PROTEIN NFKB2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER PATIENT; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DNA MICROARRAY; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREOPERATIVE EVALUATION; RECTUM BIOPSY; RECTUM CANCER; TREATMENT RESPONSE;

EID: 79955005098     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Holm T, Cedermark B and Rutqvist LE: Local recurrence of rectal adenocarcinoma after 'curative' surgery with and without preoperative radiotherapy. Br J Surg 81: 452-455, 1994.
2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H and Raab R; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
3. Nelson H and Sargent DJ: Refining multimodal therapy for rectal cancer. N Engl J Med 345: 690-692, 2001.
4. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW and van de Velde CJ; Dutch Colorectal Cancer Group: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638-646, 2001.
5. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA and Skibber J: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44: 1027-1038, 1999. (Pubitemid 29342903)
6. Kim JS, Kim JS, Cho MJ, Song KS and Yoon WH: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54: 403-408, 2002.
7. Glynne-Jones R and Harrison M: Locally advanced rectal cancer: What is the evidence for induction chemoradiation? Oncologist 12: 1309-1318, 2007.
8. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, Lin EH and Janjan NA: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97: 517-524, 2003. (Pubitemid 36133820)
9. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R and Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696, 2005. (Pubitemid 46211512)
10. Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G, Doglietto GB, Ambesi-Impiombato F and Cosimelli M: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53: 664-674, 2002. (Pubitemid 34626505)
11. Sugihara K: Response Assessment of Nonsurgical Treatment for Colorectal Carcinoma. Japanese Classification of Colorectal Carcinoma. Japanese Society for Cancer of me Colon and Rectum. First English ed. Tokyo, Kanehara & Co. Ltd., pp. 77-82, 1997.
12. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T and Ried T: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23: 1826-1838, 2005.
13. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP and Siewert JR: Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 6: 53-61, 2008. (Pubitemid 350309530)
14. Kuremsky JG, Tepper JE and McLeod HL: Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74(3): 673-688, 2009.
15. Gu ZD, Li JY, Li M, Gu J, Shi XT, Ke Y and Chen KN: Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100: 1835-1843, 2005.
16. Yamamoto H, Itoh F, Adachi Y, Fukushima H, Itoh H, Sasaki S, Hinoda Y and Imai K: Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn J Clin Oncol 29: 58-62, 1999.
17. Yamashita K, Azumano I, Mai M and Okada Y: Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 79: 187-194, 1998. (Pubitemid 28201692)
18. Leeman MF, Curran S and Murray GI: New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534, 2003. (Pubitemid 38256401)
19. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P and Matrisian LM: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891, 1999. (Pubitemid 29250878)
20. Zeng ZS, Shu WP, Cohen AM and Guillem JG: Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 8: 144-148, 2002. (Pubitemid 34101470)
21. Barcellos-Hoff MH, Derynck R, Tsang ML and Weatherbee JA: Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 93: 892-899, 1994.
22. Pardali K and Moustakas A: Actions of TGF-beta as tumor suppressor and prometastatic factor in human cancer. Biochim Biophys Acta 1775(1): 21-62, 2007. (Pubitemid 44881193)
23. Fujimoto K, Sheng H, Shao J and Beauchamp RD: Transforming growth factor-betal promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp Cell Res 266: 239-249, 2001. (Pubitemid 32579229)
24. Yan Z, Deng X and Friedman E: Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-β receptor III. J Biol Chem 276: 1555-1563, 2001. (Pubitemid 32096591)